2026-01-15 - Analysis Report
**Stock Overview**
AbbVie Inc is a multinational biopharmaceutical company.

**Return Rate Comparison**
### Cumulative Return
- Review Stock (ABBV): 182.87%
- Comparison Stock (S&P 500, VOO): 92.89%

### Divergence
- Divergence (max: 135.40, min: -20.30, current: 87.50, relative divergence: 69.20%)

### Simplicity
- The review stock outperformed the comparison stock in the last period.

**Alpha, Beta Analysis**
| **Year**       | **CAGR** | **MDD**  | **Alpha** | **Beta** | **Cap(B)** |
|------------|------|------|-------|------|-------|
| 2016-2018  | 50.0% | 16.0% | 46.0% | 1.0 | 162.9B |
| 2017-2019  | 42.0% | 21.6% | 25.0% | 1.1 | 156.5B |
| 2018-2020  | 4.0% | 21.6% | -17.0% | 0.8 | 189.4B |
| 2019-2021  | 61.0% | 20.5% | 18.0% | 0.7 | 239.3B |
| 2020-2022  | 66.0% | 18.5% | 68.0% | 0.6 | 285.6B |
| 2021-2023  | 45.0% | 18.5% | 44.0% | 0.4 | 273.9B |
| 2022-2024  | 37.0% | 18.9% | 18.0% | 0.3 | 314.1B |
| 2023-2025  | 99.0% | 18.9% | 37.0% | 0.3 | 403.8B |

**Recent Stock Price Fluctuations**
- Close: $221.89
- Last-market: {'price': 221.89, 'previousClose': 220.75, 'change': 0.52}
- 5-day SMA: $221.38
- 20-day SMA: $225.85
- 60-day SMA: $226.34

**RSI, PPO Index Indicators and Delta_Previous_Relative_Divergence**
- Market Risk Indicator (MRI): 0.70 (High Investment Recommended)
- RSI: 41.94
- PPO: -0.35
- Hybrid Signal: Buy (Cash 0%)
- Risk Level: Medium (MRI 0.70)
- Recent relative divergence change: -3.00 (-)
- 7-day Rank change: 0 (0)
- 7-day Dynamic Expected Return change: 0.00 (0)
- Expected Return (%): 36.20%

**Recent News & Significant Events**
- Assessing AbbVie (ABBV) Valuation After Recent Share Price Weakness - simplywall.st (news.google.com)
- Congress Trade: Representative Julia Letlow Just Disclosed New Stock Trades - Quiver Quantitative (news.google.com)
- BofA Cuts AbbVie (ABBV) Target While Maintaining Neutral View - Yahoo Finance (news.google.com)
- AbbVie partners with China's RemeGen on experimental tumor treatment - Reuters (news.google.com)
- AbbVie (ABBV) Stock Falls Amid Market Uptick: What Investors Need to Know - Nasdaq (news.google.com)
- Is AbbVie a Buy, Sell, or Hold in 2026? - The Motley Fool (news.google.com)

**Analyst Opinions**
- Analyst Consensus:
  - Key: Buy
  - Mean (1=StrongBuy~5=Sell): 1.93 (~Buy)
  - Opinions: 27
  - Target Price (avg/high/low): 244.59 / 289.00 / 184.00

**Comprehensive Analysis (Summary of previous items, including news)**
- AbbVie Inc outperformed the comparison stock (S&P 500) in the last period by 90.98 points.
- Market Risk Indicator is at a medium level, indicating a moderate level of risk for the investment strategy.
- Recent news and significant events include a share price weakness, potential target changes, partnerships, and changes in investment recommendations.
- Analyst consensus is at a 'Buy' rating with an average target price of $244.59.
- The Expected Return percentage for long-term investment is 36.20%.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.